Business context and reporting period
This is ZIOPHARM Oncology, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2020—not a filing under the name Alaunos Therapeutics. The company was a clinical-stage immuno-oncology developer with Sleeping Beauty cell-therapy and Controlled IL-12 gene-therapy programs. It reported no recurring operating revenue and no product sales.
Financial results and liquidity
| Metric | Q2 2020 | Q2 2019 | Six months 2020 | Six months 2019 |
|---|---|---|---|---|
| Revenue | No product revenue reported | No product revenue reported | No product revenue reported | No product revenue reported |
| Research and development | $12.1 million | $10.0 million | $24.8 million | $19.5 million |
| General and administrative | $6.6 million | $4.8 million | $12.5 million | $8.9 million |
| Total operating expenses | $18.6 million | $14.8 million | $37.3 million | $28.4 million |
| Net loss | $18.6 million | $14.6 million | $36.9 million | $28.1 million |
| Net loss per share, basic and diluted | $0.09 | $0.09 | $0.18 | $0.17 |
For the six months, operating cash use was $23.9 million, versus $18.3 million in 2019; capital expenditures were $4.0 million versus $0.1 million. Financing provided $101.7 million, mainly from a public offering and at-the-market sales. Cash and cash equivalents were $153.5 million at June 30, 2020, up from $79.7 million at year-end 2019. Working capital was $156.1 million, up from $93.0 million.
Total liabilities were $18.3 million, including $2.0 million of current and noncurrent lease liabilities; the filing reports no borrowing debt. No meaningful operating margin is available because the company had no product revenue and incurred operating losses.
Material changes versus prior comparable periods
- First-half operating expenses rose $8.9 million year over year: R&D increased $5.3 million (27%) and G&A increased $3.6 million (41%). Management attributed the R&D increase mainly to gene-therapy trial costs and higher employee expenses; G&A increases included salaries, patent-related legal costs, and facilities.
- First-half net loss widened by $8.8 million. Operating cash use increased by $5.6 million.
- The company raised $88.7 million net in a February 2020 public offering and $13.0 million net through its ATM program, issuing approximately 31.9 million shares in total. Shares outstanding were approximately 214.3 million at June 30, versus 181.8 million at December 31, 2019.
- Property and equipment increased to $5.7 million from $1.1 million, reflecting investment in Houston facilities.
Outlook, commentary, risks, and unusual items
- Management estimated existing cash would fund current operations into mid-2022, based on current development plans. The company had no committed additional capital and warned that spending could exceed estimates; financing constraints could force program delays or cuts.
- COVID-19 disrupted operations and clinical development. The NCI paused enrollment precautions for its Sleeping Beauty TCR Phase 2 trial; it had begun reopening and expected to resume screening and enrollment activities. Management also cited potential impacts on sites, patients, suppliers, and access to capital.
- Clinical updates: the Phase 2 Controlled IL-12 plus cemiplimab trial in recurrent glioblastoma completed enrollment in June 2020 (40 enrolled; 39 dosed). Management reported median overall survival of 16.2 months in unifocal patients in longer-term follow-up from two monotherapy trials. These are company-reported clinical updates, not a guarantee of later results. The company expected to submit an IND for an MD Anderson TCR trial in Q1 2021 and expected Eden BioCell to submit a Taiwan IND in 2020.
- The filing says a planned pivotal randomized trial of Controlled IL-12 plus veledimex for recurrent glioblastoma had been paused while the company addressed FDA chemistry, manufacturing, and controls requirements; there was no assurance it could meet those requirements or proceed to Phase 3.
- Key risks include clinical failure, regulatory and manufacturing delays, reliance on licensors and research partners, competition, possible need for further dilutive financing, and limited authorized shares. As of June 30, the company reported 214.2 million shares outstanding and 29.7 million shares reserved for options and warrants against 250 million authorized shares.
- Disclosure controls were deemed ineffective because a material weakness in controls over monitoring and recording third-party clinical-trial costs remained unresolved. Management said it was implementing remediation measures; it nevertheless stated the interim financial statements were fairly presented in all material respects.
- Contractual obligations listed total $9.4 million, including operating leases, NCI CRADA commitments, and royalty and license fees. Additional contingent milestone, royalty, and development obligations may arise under license agreements.
Most important facts to verify
- Confirm the issuer identity and relationship to Alaunos Therapeutics; the supplied filing is for ZIOPHARM Oncology, Inc.
- Reconcile the MD&A’s stated six-month net loss of $37.6 million and accumulated deficit of $721.7 million with the financial statements and notes, which report $36.9 million and $721.0 million, respectively.
- Check current cash runway assumptions, subsequent financing, share authorization, and dilution risk against later filings.
- Review updated trial enrollment, safety and efficacy data, FDA CMC requirements, and the effects of COVID-19 on trial timelines.
- Assess whether the clinical-cost control weakness was remediated and whether later filings report further control issues.